

Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form SC 13G

SPECTRUM PHARMACEUTICALS INC
Form SC 13G
February 14, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b) (c) AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. ___)*

Spectrum Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, \$.001 par value

(Title of Class of Securities)

84763A108

(CUSIP Number)

November 23, 2007

(Date of Event which Requires Filing of this
Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

Page 1 of 3

* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).

SCHEDULE 13G

CUSIP No. 84763A108

Page 2 of 3 Pages

Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form SC 13G

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

OTA LLC
13-3545927

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) []
(b) []

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION
DELAWARE, USA

5 SOLE VOTING POWER

2045003

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH

6 SHARED VOTING POWER

7 SOLE DISPOSITIVE POWER

2045003

8 SHARED DISPOSITIVE POWER

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

2045003

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN
SHARES* []

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

6.55%**

12 TYPE OF REPORTING PERSON

BD

**Calculation of the reporting person's percentage ownership is based on an approximate number of outstanding shares from the issuer's most recently filed quarterly or annual report.

Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form SC 13G

Page 3 of 3

- Item 1(a). Name of Issuer: Spectrum Pharmaceuticals, Inc.
- Item 1(b). Address of Issuers's Principal Executive Offices: 157 TECHNOLOGY DR
IRVINE, CA 92618
- Item 2(a). Name of Person Filing: OTA LLC
IRS No. 13-3545927
- Item 2(b). Address of Principal Business Office or, if None, Residence: ONE MANHATTANVILLE ROAD
PURCHASE, NY 10577
- Item 2(c). Citizenship: USA
- Item 2(d). Title of Class of Securities: Common Stock
- Item 2(e). CUSIP Number: 84763A108
- Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
- (a) Broker or dealer registered under Section 15 of the Exchange Act.
 - (b) Bank as defined in Section 3(a)(6) of the Exchange Act.
 - (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act.
 - (d) Investment company registered under Section 8 of the Investment Company Act.
 - (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
 - (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
 - (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
 - (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
 - (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
 - (j) Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form SC 13G

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:

The reporting person has, as of November 23, 2007, the right to acquire beneficial ownership of the common stock of the issuer within 60 days through the exercise of 2045003 warrants. The reporting person would beneficially own 2045003 common shares of the issuer upon the exercise of these warrants.

(b) Percent of class:

6.55%

This number represents the percentage ownership based on the right to acquire the common stock of the issuer within 60 days upon the exercise of the above referenced warrants.

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote,

2045003
See Item 4(a)

(ii) Shared power to vote or to direct the vote 0,

(iii) Sole power to dispose or to direct the disposition of,

2045003
See Item 4(a)

(iv) Shared power to dispose or to direct the disposition of 0

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities check the following [].

N/A

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

N/A

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

N/A

Item 8. Identification and Classification of Members of the Group.

Edgar Filing: SPECTRUM PHARMACEUTICALS INC - Form SC 13G

N/A

Item 9. Notice of Dissolution of Group.

N/A

Item 10. Certifications.

(a) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(b):

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect."

(b) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(c):

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect."

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 14, 2008

(Date)

/s/ JOHN HANRATTY

(Signature)

JOHN HANRATTY, CHIEF COMPLIANCE OFFICER

(Name/Title)

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).